ASC 63
Alternative Names: ASC-63Latest Information Update: 19 Dec 2021
At a glance
- Originator Ascletis
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Dec 2021 ASC 63 is available for licensing as of 03 Dec 2021. https://ascletis.com/single3/136.html
- 03 Dec 2021 Preclinical trials in Solid tumours in China (PO) as of December 2021 (Ascletis pipeline, December 2021)
- 05 Nov 2021 Pharmacodyanmics data from a preclinical trial in Solid tumours released by Ascletis